Opendata, web and dolomites

CanFaster SIGNED

The Translational Cancer Faster Forward doctoral programme – CanFaster

Total Cost €


EC-Contrib. €






Project "CanFaster" data sheet

The following table provides information about the project.


Organization address
address: Paradisgatan 5c
city: Lund
postcode: 22100

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website
 Total cost 3˙348˙480 €
 EC max contribution 1˙674˙240 € (50%)
 Programme 1. H2020-EU.1.3.4. (Increasing structural impact by co-funding activities)
 Code Call H2020-MSCA-COFUND-2016
 Funding Scheme MSCA-COFUND-DP
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2022-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUNDS UNIVERSITET SE (Lund) coordinator 1˙674˙240.00


 Project objective

CanFaster is a joint venture among industry, health care and academia to enhance and accelerate innovations and clinical implementation within oncology. The vision of CanFaster is to prolong and save lives of cancer patients through integrated development and commercialization/implementation of diagnostic/treatment alternatives, thus reaching the market and patient more rapidly. CanFaster will save lives of cancer patients, not for future generations, but for today´s. The CanFaster programme is enabled by an intimate collaboration between industry, health care system and academia (in total ~7 million Euro will be invested), and will contribute to the Europe 2020 strategy, where one million new research jobs are needed to reach the Innovation Union flagship initiative. The collected track record of all partners in the proposed CanFaster programme demonstrates an impressive history of entrepreneurial spirit, state-of the art medical care but also truly world-class scientific excellence within translational cancer research. The CanFaster regional doctoral programme, recruiting 16 ESRs, will be hosted within CREATE Health, a translational cancer research programme with broad international collaboration partners and excellent out-put for the last 10 years. Main objectives of CanFaster are (i) Increased transnational and intersectorial mobility (ii) Intersectorial improvements through intensified collaboration within oncology between academia, industry and hospital/regional health care organisations. (iii) Acceleration of innovation, attracting international investors leading to increased number of SMEs in the region and (iv) Education of a new generation of excellent multidisciplinary, entrepreneurial scientists. This is achieved through the attraction of the MSCA program for industrial partners to add-on to the EU and public national funding of the programme with financial and in-kind contribution.


year authors and title journal last update
List of publications.
2020 Julio Enríquez Pérez, Jan Kopecky, Edward Visse, Anna Darabi, Peter Siesjö
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas
published pages: , ISSN: 1471-2407, DOI: 10.1186/s12885-019-6502-7
BMC Cancer 20/1 2020-03-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANFASTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANFASTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.4.)

oLife (2019)

The origin and evolution of Life in the universe

Read More  


ENhanced PhD Fellowship Programme in the Sciences of LIGHT

Read More  

ARDRE (2019)

Ageing, Regeneration, and Drug Research

Read More